+

PE20030335A1 - Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad - Google Patents

Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad

Info

Publication number
PE20030335A1
PE20030335A1 PE2002000803A PE2002000803A PE20030335A1 PE 20030335 A1 PE20030335 A1 PE 20030335A1 PE 2002000803 A PE2002000803 A PE 2002000803A PE 2002000803 A PE2002000803 A PE 2002000803A PE 20030335 A1 PE20030335 A1 PE 20030335A1
Authority
PE
Peru
Prior art keywords
obesity
systems
treatment
indan
prophylaxia
Prior art date
Application number
PE2002000803A
Other languages
English (en)
Inventor
Martin Bickel
Volker Krone
Gerhard Jaehne
Matthias Gossel
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20030335A1 publication Critical patent/PE20030335A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UTILIZACION DE COMPUESTOS INDAN-1-OL-SUSTITUIDOS EN C2 DE FORMULA I DONDE R1, R2, R3, R4 SON H, F, Cl, Br, I, CN, NO2, OH, O-ALQUILO C1-C8, O-CICLOALQUILO C3-C8, O-CH2-FENILO, O-FENILO, O-CO-ALQUILO C1-C8, 5-TETRAZOLILO, ENTRE OTROS; X ES S, SO, SO2; Y ES (CH2)p; p ES 0-3; R5 ES CF3, ALQUILO C1-C18, CICLOALQUILO C3-C8, (CH2)r-COR6, CH2-CH(NHR7)COR8, FENILO, NAFTILO, BIFENILO, HETEROCICLO, r ES 1-6; R6 Y R8 SON OH, ALQUILO C1-C6, NH2; R7 ES H, CO-ALQUILO C1-C4. SON COMPUESTOS PREFERIDOS 5-CLORO-2-METILSULFONIL-INDAN-1-ONA, 5-CLORO-2-(PROPAN-2-SULFONIL)-INDAN-1-OL, 5-CLORO-2-ETANOSULFONIL-INDAN-1-OL; 5-CLORO-2-METILSULFANIL-INDAN-1-OL. TAMBIEN SE REFIERE AL USO CON CATINAS, FENILPROPANOLAMINAS, AMFEPRAMONAS, MEFENOREX, EFEDRINAS, LEPTINA, DEXANFETAMINAS, ANFETAMINAS, FENFLURAMINAS, ENTRE OTROS. LOS COMPUESTOS TIENEN EFECTO ANOREXICO Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE OBESIDAD
PE2002000803A 2001-08-31 2002-08-21 Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad PE20030335A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10142666A DE10142666A1 (de) 2001-08-31 2001-08-31 Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas

Publications (1)

Publication Number Publication Date
PE20030335A1 true PE20030335A1 (es) 2003-05-20

Family

ID=7697236

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000803A PE20030335A1 (es) 2001-08-31 2002-08-21 Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad

Country Status (13)

Country Link
US (2) US20030134879A1 (es)
EP (1) EP1425007B1 (es)
JP (1) JP2005503397A (es)
AT (1) ATE308321T1 (es)
AU (1) AU2002336984B2 (es)
CA (1) CA2458526A1 (es)
DE (2) DE10142666A1 (es)
DK (1) DK1425007T3 (es)
ES (1) ES2250710T3 (es)
IL (2) IL160605A0 (es)
MX (1) MXPA04001852A (es)
PE (1) PE20030335A1 (es)
WO (1) WO2003020263A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142663B4 (de) 2001-08-31 2004-08-19 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-ol-Systeme
JP5640019B2 (ja) * 2009-01-26 2014-12-10 タイペイ・メディカル・ユニバーシティTaipei Medical University 糖尿病及び肥満症を治療するためのプテロシン化合物の使用
US12162820B2 (en) * 2019-03-29 2024-12-10 Taiwanj Pharmaceuticals Co., Ltd. Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2345146A1 (fr) * 1976-03-23 1977-10-21 Logeais Labor Jacques Nouveau medicament a base d'(hydroxy-2 indanyl-2) 1-propanol
DE2965279D1 (en) * 1978-07-27 1983-06-01 Schering Ag Indanyl derivatives, process for their preparation and pharmaceutical compositions containing these compounds
WO1987002035A1 (en) * 1985-10-04 1987-04-09 Maggioni-Winthrop S.P.A. Fused cycloaliphatic aminoalcohols
MX13484A (es) 1987-10-19 1993-05-01 Pfizer Procedimiento para la obtencion de tetralinas, cromanos y compuestos relacionados, sustituidos
AU1169397A (en) * 1995-12-06 1997-06-27 Venantius Limited Indane compounds with smooth muscle relaxing and/or mast cell stabilising and/or anti-inflammatory activity
WO1997026265A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
DK0944648T3 (da) 1996-08-30 2007-07-02 Novo Nordisk As GLP-1 derivater
RU2200161C2 (ru) 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
CA2294830A1 (en) 1997-07-16 1999-01-28 John Bondo Hansen Fused 1,2,4-thiadiazine derivatives, their preparation and use
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
DE10142660A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142662B4 (de) * 2001-08-31 2004-07-08 Aventis Pharma Deutschland Gmbh Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
DE10142667B4 (de) * 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
JP2005503397A (ja) 2005-02-03
IL160605A0 (en) 2004-07-25
WO2003020263A1 (de) 2003-03-13
US20030134879A1 (en) 2003-07-17
MXPA04001852A (es) 2004-06-15
US7763662B2 (en) 2010-07-27
DE50204801D1 (de) 2005-12-08
EP1425007B1 (de) 2005-11-02
AU2002336984B2 (en) 2006-10-26
DK1425007T3 (da) 2006-03-13
US20050080057A1 (en) 2005-04-14
ES2250710T3 (es) 2006-04-16
IL160605A (en) 2010-12-30
EP1425007A1 (de) 2004-06-09
CA2458526A1 (en) 2003-03-13
DE10142666A1 (de) 2003-03-20
ATE308321T1 (de) 2005-11-15

Similar Documents

Publication Publication Date Title
NO20052739L (no) CCR5-antagonister som medikamenter
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
DE60318891D1 (de) Cyclopropylverbindungen als ccr5 antagonisten
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
ATE405269T1 (de) Cyclohexylverbindungen als ccr5-antagonisten
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO20081844L (no) Terapeutiske forbindelser
ATE520668T1 (de) Sigmarezeptor-inhibitoren
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
PT1173176E (pt) Utilizacao de sistemas policiclicos de 2-amino-tiazole para a preparacao de medicamentos para a profilaxia ou tratamento da obesidade
BR0208038A (pt) Uso de um ou mais componentes saudáveis e método para a administração de um componente saudável.
BR0008519A (pt) Aplicação de sistemas tiazol policìclicos para apreparação de medicamentos para a profilaxia outratamento da obesidade
PE20030335A1 (es) Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad
PE20030338A1 (es) Utilizacion de derivados de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
IL160603A0 (en) C2-disubstituted indan-1-ol systems and their derivatives, processes for their preparation and their use as pharmaceuticals
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
PE20030337A1 (es) Indan-1-onas sustituidas en c2 y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentos
UY26945A1 (es) Alcanosulfonatos de fenoxifenilo
MXPA04001853A (es) Uso de sistemas de indan-1-ona c2-substituida para producir medicamentos para la profilaxis o tratamiento de obesidad.
DOP2001000253A (es) Alcanosulfonatos de fenoxifenilo.

Legal Events

Date Code Title Description
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载